Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Apellis Pharmaceuticals Inc
APLSCurrent price
41.05 USD
+1.38 USD (+3.48%)
Last closed
39.29 USD
Company
www.apellis.com
ISIN
US03753U1060
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
4 736 697 344 USD
Yield for 12 month
-4.51 %
1Y
3Y
5Y
10Y
15Y
APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
70.5 USDP/E ratio
–Dividend Yield
–Current Year
+396 591 000 USD
Last Year
+75 422 000 USD
Current Quarter
+199 685 000 USD
Last Quarter
+172 325 000 USD
Current Year
+336 377 000 USD
Last Year
+69 786 000 USD
Current Quarter
+176 136 000 USD
Last Quarter
+151 672 000 USD
Key Figures APLS
1 year
3 years
5 years
10 years
EBITDA
-311 300 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-21.51 %
PEG Ratio
–
Return On Equity TTM
-109.19 %
Wall Street Target Price
70.5 USD
Revenue TTM
628 785 984 USD
Book Value
2.17 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
110.3 %
Dividend Yield
–
Gross Profit TTM
69 786 000 USD
Earnings per share
-2.72 USD
Diluted Eps TTM
-2.72 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-52.94 %
Dividend Analytics APLS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History APLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation APLS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
7.7151
Price Sales TTM
7.5331
Enterprise Value EBITDA
-12.123
Price Book MRQ
17.9199
Financials APLS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators APLS
For 52 weeks
33.49 USD
73.8 USD
50 Day MA
37.99 USD
Shares Short Prior Month
15 916 603
200 Day MA
50.94 USD
Short Ratio
9.32
Shares Short
16 267 681
Short Percent
18.44 %
BeatStart